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Abstract
Background: Sleep disturbance is a common complaint in patients with chronic obstructive lung disease (COPD).
However, the factors resulting in sleep disturbance remain unclear. This retrospective, observational, multicenter
study aimed to identify the factors associated with sleep disturbance in patients with COPD.
Methods: The study was a retrospective, observational, and multicenter research. Data including age, sex, body
mass index, smoking status, COPD inhaler prescribed, clinical symptoms, pulmonary function tests, medical history
of comorbidities, and questionnaires were collected. Parameters including demographics, symptoms, medication,
severity, functional classification, and comorbidities were correlated with sleep quality scores.
Results: Among 377 patients with COPD, 200 (53 %) patients experienced poor sleep quality (Pittsburg Sleep Quality
Index scores > 5). A significant difference in sleep quality, as measured by PSQI scores, was noted between groups
based on the 2011 Global Initiatives for Chronic Obstructive Lung Disease (GOLD) classification system. The most
common sleep disturbances included “getting up to use the bathroom” (70.3 %), “wake up at night or early morning”
(40.3 %), and “cough and snore loudly at night” (15.9 %). The use of inhaled corticosteroids, the presence of wheezing,
COPD Assessment Test (CAT) scores, and Modified Medical Research Council (mMRC) dyspnea scale scores positively
correlated with poor sleep quality (odds ratio: 1.51, 1.66, 1.09, and 1.30, respectively). Upon multivariate analysis, the
CAT score was an independent factor for poor sleep quality in these patients. With the exception of sleep problem
items, based on the CAT questionnaire, phlegm was significantly higher in COPD patients with poor sleep quality.
Conclusions: Poor sleep quality is common among patients with COPD and symptoms including wheeze, phlegm,
and inhaled corticosteroid use may contribute to poor sleep quality. The CAT score is a good indicator of poor sleep
quality in patients with COPD.
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Background
Sleep disturbance is a common symptom in patients
with COPD [1, 2] and there are significant differences
between the sleep disorders in patients with COPD and
those encountered in the general population [3]. Less
rapid eye movement (REM) sleep and arousals during
periods of desaturation are often noted in patients with
COPD [4]. Patients with COPD also become more hyp-
oxemic during sleep than when awake and the hypox-
emia during sleep is even greater than that encountered
during exercise [5]. Hypoventilation is the major cause
of hypoxemia during REM sleep in patients with COPD
and there may be additional contributions from ventilation-
perfusion mismatches and reductions in functional residual
capacity [6].
Recently, Nunes et al. [1] reported that 70 % of patients
with COPD had poor sleep quality, and the quality of
sleep was the major determinant of quality of life in those
patients. In the study by Scharf et al. [2] sleep quality was
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also associated with quality of life and sleep disturbance
predicted poor survival in patients with COPD [7]. How-
ever, the factors resulting in sleep disturbance are not well
understood.
In patients with moderate to severe COPD, nocturnal
desaturation did not correlate with sleep quality or qual-
ity of life [8]. In another study, disturbed sleep was cor-
related with cough and dyspnea symptoms, but not with
forced expiratory volume in the first second (FEV1) in
patients with COPD [7]. In addition, whether current pul-
monary medications for COPD, including anticholiner-
gics, theophylline, steroids, and beta2 agonists could
improve or impair sleep quality is not well known [9–14].
This study was conducted, therefore, to identify the fac-




This study was conducted in accordance with the
amended Declaration of Helsinki. The study was ap-
proved by the Institutional Review Boards of all the hos-
pitals involved.
A retrospective, observational, multicenter research
study was performed across six participating hospitals, in-
cluding four medical centers and two regional hospitals,
three in northern Taiwan, one in center-western Taiwan,
two in southwestern Taiwan. Between December 2011
and November 2013, patients over 40 years of age with
COPD, who were followed in an outpatient pulmonary
clinic, were enrolled. Patients with a COPD diagnosis,
based on the Global Initiatives for Chronic Obstructive
Lung Disease (GOLD) guidelines, were included [15]. The
GOLD guidelines are used worldwide in the diagnosis and
management of COPD. COPD severity is staging by lung
function only according to old GOLD guideline [16].
According to the 2007 GOLD definition: Stage 1:
FEV1 ≥ 80 % predicted; Stage: 2 FEV1 < 80 % predicted
and ≥ 50 % predicted; Stage 3: FEV1 < 50 % predicted
and ≥30 % predicted; and Stage 4: FEV1 < 30 % pre-
dicted. In the GOLD guideline updated in 2011, COPD
patients are classified into four groups by their symp-
toms and lung function [15]. COPD symptoms were
evaluated by mMRC or CAT as follows: less symptoms
patient (A or C) : mMRC 0–1 or CAT < 10; More symp-
toms patients (B or D): mMRC ≥ 2 or CAT ≥ 10. Low risk
patients (A or B): FEV1% predicted ≥ 50 % or COPD ex-
acerbation history 0–1; High risk patients (C or D):
FEV1% predicted < 50 % or COPD exacerbation his-
tory ≥ 2. The patients with COPD are categorized into
A, B, C, and D, four groups.
All participants had pulmonary function tests within
one year and at least one COPD Assessment Test (CAT)
[17], one Modified Medical Research Council (mMRC)
dyspnea scale [18], and one Pittsburgh Sleep Quality
Index (PSQI) [19]. Patients with a history of bronchial
asthma or malignancy were excluded.
Data collection
Medical records were retrospectively reviewed and ana-
lyzed for the following data: age, sex, body mass index
(BMI), smoking status, COPD medications prescribed at
Table 1 Demographic characteristics of the study population
(n = 377)
Characteristics Mean ± SD
Age, years 73.0 ± 10.1
Male sex, n (%) 371 (98.4 %)
BMI, (kg/m2) 23.6 ± 3.0
Smoking history
Never smoker, n (%) 22 (6.0 %)
Ex-smoker, n (%) 232 (63.0 %)
Current smoker, n (%) 114 (31 %)
FEV1, L 1.4 ± 0.5
FEV1, predicted % 59.8 ± 23.0
Exacerbation in previous year, times 0.6 ± 1.2
Comorbidities
Cardiovascular disease, n (%) 157 (41.6 %)
Ischemic heart disease, n (%) 35 (9.3 %)
Heart failure, n (%) 15 (4.0 %)
Hypertension, n (%) 129 (34.2 %)
Arrhythmia, n (%) 19 (5.0 %)
Depression, n (%) 10 (2.7 %)
Maintenance inhaler
LABA, n (%) 18 (4.8 %)
LAMA, n (%) 87 (23.1 %)
LABA/LAMA, n (%) 21 (5.6 %)
LABA/ICS, n (%) 72 (19.1 %)
LAMA/ICS, n (%) 3 (0.8 %)
LABA/LAMA/ICS, n (%) 90 (23.9 %)
No maintenance inhaler, n (%) 86 (22.8 %)
GOLD classification
Group A, n (%) 60 (15.9 %)
Group B, n (%) 150 (39.8 %)
Group C, n (%) 34 (9.0 %)
Group D, n (%) 133 (35.3 %)
PSQI score
PSQI >5, n (%) 200 (53.1 %)
PSQI≦5, n (%) 177 (46.9 %)
Abbreviations: BMI body mass index, GOLD Global Initiative for Chronic
Obstructive Lung Disease, FEV1 forced expiratory volume in the first second,
FVC forced vital capacity, ICS inhaled corticosteroids, LABA long-acting beta
agonists, LAMA long-acting muscarinic antagonist, PSQI Pittsburgh sleep
quality index
Chang et al. BMC Pulmonary Medicine  (2016) 16:118 Page 2 of 8
outpatient clinics, clinical symptoms, presence of wheez-
ing recorded in the medical charts, pulmonary function
tests, and medical history of comorbidities. The COPD
maintenance inhaler was defined as an inhaler continu-
ously prescribed for 3 months.
Measures
The PSQI is a self-rating screening tool that measures
quality of sleep. In addition to a total score, PSQI provides
seven components of sleep including quality, latency, dur-
ation, efficiency, sleep disturbances, use of sleeping me-
dication, and daytime dysfunction. Each component is
scored from 0 to 3, and seven component scores are then
summed to gain a global score [19]. A PSQI global
score > 5 indicates poor sleep quality [19]. The trad-
itional Chinese version of PSQI was used to assess sleep
quality in this study [20]. The results of the PSQI ques-
tionnaire were retrospectively collected and analyzed.
The CAT is a questionnaire for assessing the health sta-
tus of COPD [17]. The test has eight items including
cough, phlegm, chest tightness, breathlessness, activ-
ities, confidence, sleep, and energy. Each item can be
scored as a single scale (from 0 to 5) with total scores ran-
ging from 0 to 40. Higher CAT scores indicate poorer
health. The modified Medical Research Council (mMRC)
scale include five statements for rating dyspnea from 0 to
4, and higher mMRC grades indicate more dyspnea [18].
According to the GOLD guidelines, either a mMRC ≥ 2 or
a CAT score ≥ 10 indicate more symptoms [15].
Statistical analysis
Patient demographics, clinical characteristics, and medica-
tion use were summarized using descriptive statistics and
data were expressed as mean ± standard deviation (SD).
Comparisons between groups were made using the in-
dependent t-test, Chi-square test, one-way ANOVA, or
Kruskal-Wallis one-way analysis of variance, where appro-
priate. Potential risk factors causing poor sleep quality in
patients with COPD, including age, BMI, lung function,
clinical symptoms, medications, medical history of comor-
bidities, and symptoms scores, were analyzed using uni-
variate and multivariate analysis by applying a multiple
logistic regression. All statistical analyses were performed
using the using Statistical Analysis Software (SAS) version
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 377 stable patients with COPD and who
attended the outpatient clinic and fulfilled the study criteria
were analyzed. Table 1 shows the patients’ characteristics,
including age, sex, BMI, FEV1% predicted, FVC% pre-
dicted, GOLD group, comorbidities, and current COPD
medication. Most patients were elderly and 98 % were
male. According to the GOLD classification, most patients
were classified into GOLD groups B and D. Among those
classified, 53 % had poor sleep quality (PSQI > 5).
Patients with COPD were divided by their pulmonary
function tests according to the 2007 GOLD classification
[16]. Based on the 2007 GOLD classification system, the
percentages of subjects with PSQI scores greater than 5
among the four groups was not significant (Table 2).
The COPD patients were also classified using the 2011
GOLD classification system [15], and the percentages of
patients with PSQI >5 between the GOLD groups A, B,
C, and D were 43.3, 54.0, 38.2, and 60.2 %, respectively
(p < 0.05) (Table 3).
Table 4 demonstrated the specific components obtained
from the PSQI. Among the seven components, sleep dis-
turbance achieved the highest score compared with the
other components. The most common sleep disturbances
were “getting up to use the bathroom” (70.3 %), “wake up
at night or early morning” (40.3 %) and “cough and snore
loudly at night” (15.9 %). The percentage of the symptoms
of sleep disturbance had no statistical difference between
different stages of COPD according to the GOLD 2007
classification. (Table 5) We divided the subjects by the
2011 GOLD classification, patients had high percentage of
“wake up at night or early morning” and “get up to use
the bathroom” on GOLD group B and group D (Table 6).
Table 7 shows the results of univariate analysis of vari-
ables associated with poor sleep quality (PSQI > 5) in pa-
tients with COPD based on logistic regression. Inhaled
corticosteroids and the presence of a wheeze showed posi-
tive correlations with poor sleep quality scores with odds
ratios (ORs) of 1.66 and 1.51, respectively. The CAT and
MMRC scores also correlated with PSQI scores with ORs
Table 2 Measurements of COPD based on the 2007 GOLD classification
GOLD Stage 1 GOLD Stage 2 GOLD Stage 3 GOLD Stage 4 P-value
N = 68 N = 161 N = 123 N = 25
MMRC, mean ± SD 1.50 ± 0.76 1.78 ± 0.75 1.96 ± 0.95 2.33 ± 1.09 <0.001
CAT, mean ± SD 9.15 ± 6.91 9.53 ± 6.35 11.07 ± 7.11 16.83 ± 8.29 <0.001
PSQI score, mean ± SD 6.54 ± 3.57 6.43 ± 3.50 6.33 ± 3.66 6.44 ± 3.16 0.970
PSQI >5, n (%) 36 (52.9) 85 (52.8) 64 (52.0) 15 (60.0) 0.910
Abbreviations: CAT COPD assessment test, GOLD Global Initiative for Chronic Obstructive Lung Disease, mMRC modified Medical Research Council, PSQI, Pittsburgh
Sleep Quality Index
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of 1.09 (95 % confidence interval [CI], 1.05–1.13) and 1.30
(95 % CI, 1.02–1.66), respectively. Upon multivariate ana-
lysis, the CAT score remained an independent factor in
poor sleep quality with an OR of 1.09 (95 % CI, 1.04–1.14;
p < 0.001).
To explore the factors contributing to poor sleep quality
using the CAT score, the differences in CAT items be-
tween good and poor sleepers were further analyzed.
Among all participants, 131 patients had all detailed spe-
cific items on COPD assessment tests recorded. Not sur-
prisingly, “sleep problem” was one factor in poor sleepers.
However, in addition, higher phlegm production was a sig-
nificant factor in poor sleepers (Table 8).
Discussion
Our study demonstrated that 53 % of patients with COPD
in our cohort had poor sleep quality (PSQI score > 5). A
high prevalence of poor sleep quality in patients with
COPD has been reported in previous studies [1, 2, 8]. In a
recent real-world study, 78 % of patients with COPD
reported night time disturbances as measured by the
Jenkins Sleep Questionnaire [21]. In a telephone study,
Ohayon reported COPD subjects had higher insomnia
symptoms than non-COPD subjects (48.1 versus 27.6 %
respectively) [22].
Our study also confirmed sleep disturbances, as well
as cough and dyspnea, as major concerns in patients
with COPD. Some researchers suggest that poor sleep
quality might result in cognitive dysfunction, depression,
anxiety, poor survival and poor quality of life [7].
Determining which factors are associated with sleep
disturbances in patients with COPD may improve their
treatment strategy.
A high prevalence of sleep symptoms among patients
with COPD was discovered approximately thirty years
ago [23] but poor sleep quality remained a forgotten di-
mension of COPD until recently [24]. Few studies, how-
ever, have addressed factors such as medical history,
pulmonary function tests, COPD medication, and ques-
tionnaires when analyzing sleep disturbances in COPD
patients.
In this study, poor sleep quality was defined according to
PSQI scores and included several symptoms. Interestingly,
the most common symptoms that disturbed sleep in our
COPD cohort were “getting up to use the bathroom”
(69.9 %) and “wake up at night or early morning” (40.3 %)
whereas “cough and snore loudly at night” or “bad dream”
comprised the third and fourth complaints (15.9 and
11.9 %, respectively). Breathlessness, cough, sputum pro-
duction, and wheezing were also among the most common
symptoms in patients with COPD. In our study, we found
the GOLD guideline updated in 2011, which was classified
by their symptoms as well as lung function were related to
sleep disturbance as shown in Tables 2, 3, 5, and 6. More
symptoms patients (group B or group D; mMRC ≥ 2 or
CAT ≥ 10) had a higher percentage of sleep disturbance in-
cluding wake up at night or early morning, get up to use
the bathroom, bad dream and cannot breathe comfortably.
In a nation-wide longitudinal population study, the
overall prevalence of nocturnal voiding was 56 % at
50 years of age increasing to 74 % 10 years later [25]. The
average age of our cohort was 73 years of age with 69.9 %
complaining of nocturnal voiding symptoms, similar to
the results from the population study. An epidemiological
study of nocturia by Yoshimura et al. suggested that, be-
sides benign prostate hypertrophy, nocturia correlated
with age, race, medical problems (such as hypertension,
diabetes, and stroke) psychological problems, quality of
life and mortality [26]. Stephenson et al. reported that use
of inhaled anticholinergic medications was associated with
an increased risk of acute urinary retention in men with
COPD, especially in those patients with benign prostate
hyperplasia [27]. However, another study concluded that
Table 4 Sleep component scores based on the PSQI in patients
with COPD
Components Mean ± SD
Sleep quality 0.97 ± 0.75
Sleep latency 1.16 ± 1.09
Sleep duration 1.11 ± 0.94
Sleep efficiency 0.73 ± 1.04
Sleep disturbance 1.50 ± 0.59
Use of sleeping medication 0.47 ± 1.03
Daytime dysfunction 0.48 ± 0.66
Abbreviation: PSQI Pittsburgh Sleep Quality Index
Table 3 Measurements of COPD based on 2011 GOLD classification
GOLD group A GOLD group B GOLD group C GOLD group D P-value
N = 60 N = 150 N = 34 N = 133
MMRC, mean ± SD 0.87 ± 0.34 2.05 ± 0.58 0.72 ± 0.46 2.31 ± 0.81 <0.001
CAT, mean ± SD 4.52 ± 2.14 11.09 ± 6.75 4.74 ± 2.69 13.84 ± 7.08 <0.001
PSQI score, Mean ± SD 5.63 ± 2.92 6.67 ± 3.68 5.03 ± 3.29 6.85 ± 3.57 0.008
PSQI >5, n (%) 26 (43.3 %) 81 (54.0 %) 13 (38.2 %) 80 (60.2 %) 0.046
Abbreviations: CAT COPD assessment test, GOLD Global Initiative for Chronic Obstructive Lung Disease, mMRC modified Medical Research Council, PSQI Pittsburgh
Sleep Quality Index
Chang et al. BMC Pulmonary Medicine  (2016) 16:118 Page 4 of 8
tiotropium did not affect lower urinary tract function in
patients with COPD [28]. In our study, the use of inhaled
long-acting muscarinic antagonists was not associated
with poor sleep quality in the COPD patients. In patients
with heart failure, nocturia is common and associated with
sleep disturbance [29]. Heart failure may be one of the fac-
tors contributing to sleep disturbance in the patients with
COPD. Although the most common cause of sleep dis-
turbance was getting up to use the bathroom, patients
with poor sleep quality also had more complaints of “wake
up at night or early morning”, “cough or snore loudly”,
and “cannot breathe comfortably” compared with those
patients without poor sleep quality. Thus, the current
study offers physicians significant information regarding
ways to discover and solve sleep problems in patients with
COPD. In a national epidemiology survey in Taiwan [30],
males were predominated, especially in current and
former smokers from 91 to 84 %. Our result had similar
male predominant population which may due to our pa-
tients are mostly current or formal smokers.
Multivariate analysis showed that high CAT scores
predicted poor sleep quality. These results implied that
surveying the causes of sleep disturbance was important
for patients with CAT scores > 10. Mehta et. al also re-
ported that COPD patients with high CAT scores had a
higher frequency of insomnia than those with low CAT
scores [31]. A previous study reported an increased
prevalence of night symptoms as the severity of airflow
limitation increased [32]. In contrast, another study
found that FEV1 was not associated with disturbed sleep
nor with health related quality of life [7, 33]. In our
study, we found no relationship between pulmonary
function tests and poor sleep quality. This result implies
that poor sleep quality is not directly related to pulmon-
ary function tests. However, other underlying diseases,
medical comorbidities, and adverse effects of drug ther-
apy may be associated factors.
The causes of sleep disturbance in patients with
COPD are multifactorial, includes respiratory symptoms
[34], obstructive sleep apnea (OSA), psychiatric disor-
ders, and medication-related insomnia [9, 35]. Sleep
disturbances due to COPD medications is a common
problem, and oral steroids, inhaled steroids, beta ago-
nists, and theophylline have been implicated [10, 36–38].
In our studies, the presence of wheeze, inhaled ICS, and
significant phlegm production contributed to poor sleep
quality. After multivariate analysis, however, no single
medication caused poor sleep quality; only the CAT score
predicted poor sleep quality in our COPD population.
“Much phlegm” on the CAT questionnaire in our cohort
was significant in poor sleepers. The CAT score is a simple
questionnaire developed to assess and monitor the
Table 6 The distribution of sleep disturbances among patients with COPD based on 2011 GOLD classification
Items reporting ≥ 3 times per week GOLD group A GOLD group B GOLD group C GOLD group D P-value
N (%) N (%) N (%) N (%)
Wake up at night or early morning 15 (25.0 %) 70 (46.7 %) 10 (29.4 %) 57 (42.9 %) 0.015
Get up to use the bathroom 37 (61.7 %) 114 (76.0 %) 19 (55.9 %) 95 (71.4 %) 0.047
Cannot breathe comfortably 0 (0.0 %) 11 (7.3 %) 2 (5.9 %) 15 (11.3 %) 0.050
Cough or snore loudly 8 (13.3 %) 21 (14.0 %) 4 (11.8 %) 27 (20.3 %) 0.383
Feel too cold 0 (0.0 %) 4 (2.7 %) 0 (0.0 %) 2 (1.5 %) 0.452
Feel too hot 0 (0.0 %) 4 (2.7 %) 0 (0.0 %) 3 (2.3 %) 0.487
Bad dreams 4 (6.7 %) 26 (17.3 %) 1 (2.9 %) 14 (10.5 %) 0.035
Pain 1 (1.7 %) 9 (6.0 %) 2 (5.9 %) 8 (6.0 %) 0.597
Table 5 The distribution of sleep disturbances among patients with COPD based on 2007 GOLD classification
Items reporting≥ 3 times per week GOLD Stage 1 GOLD Stage2 GOLD Stage 3 GOLD Stage 4 P-value
N (%) N (%) N (%) N (%)
Wake up at night or early morning 29 (42.6 %) 66 (41.0 %) 43 (35.0 %) 14 (56.0 %) 0.240
Get up to use the bathroom 45 (66.2 %) 118 (73.3 %) 80 (65.0 %) 22 (88.0 %) 0.085
Cannot breathe comfortably 2 (2.9 %) 11 (6.8 %) 11 (8.9 %) 4 (16.0 %) 0.161
Cough or snore loudly 10 (14.7 %) 23 (14.3 %) 21 (17.1 %) 6 (24.0 %) 0.628
Feel too cold 0 (0.0 %) 4 (2.5 %) 2 (1.6 %) 0 (0.0 %) 0.508
Feel too hot 0 (0.0 %) 4 (2.5 %) 2 (1.6 %) 1 (4.0 %) 0.512
Bad dreams 9 (13.2 %) 21 (13.0 %) 13 (10.6 %) 2 (8.0 %) 0.829
Pain 3 (4.4 %) 8 (5.0 %) 7 (5.7 %) 2 (8.0 %) 0.910
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symptoms of COPD [17]. We recommend the use of the
CAT questionnaire rather than the MMRC to monitor
symptoms of COPD because sleep disturbance is a major
complaint in patients with COPD.
Our study had several limitations. We did not perform
polysomnography to rule out sleep disorders such as
OSA. Although OSA is prevalent in some selected COPD
patients, the prevalence rate of OSA in patients with
COPD was similar to the general population in the other
reports [24, 39]. In addition, not all the factors which dis-
turbed sleep (such as depression) were collected. The
subjects included in our study may have had more medical
comorbidities (and the percentage of GOLD B and D
patients may have been higher) than those found in the
general COPD population. Finally, the study was retro-
spective and the most data were collected in older men
with COPD.
Conclusions
More than half of our patients with COPD experienced
poor sleep quality. The most common sleep complaints
included getting up for the bathroom, waking up at
Table 8 Specific items on COPD Assessment Test between patients with COPD with poor sleep quality (PSQI > 5) and those without
poor sleep quality
With poor sleep quality (N = 86) Without poor sleep quality (N = 45) P-value
Cough 2.0 ± 1.7 1.6 ± 1,3 0.123
Phlegm* 2.4 ± 1.6 1.8 ± 1.5 0.030
Chest tightness 1.4 ± 1.4 1.1 ± 1.5 0.286
Breathlessness 2.4 ± 1.7 2.2 ± 1.9 0.558
Activities 1.0 ± 1.4 1.0 ± 1.6 0.805
Confidence 1.1 ± 1.5 1.1 ± 1.7 0.953
Sleep* 2.1 ± 1.9 0.7 ± 1.4 <0.001
Energy 1.8 ± 1.6 1.4 ± 1.7 0.176
CAT score* 14.4 ± 8.1 11.0 ± 7.9 0.022
*p < 0.05
Table 7 Variables associated with poor sleep quality among patients with COPD
Characteristics Parameter estimate Standard error Odds ratio (95 % CI) P-value
Univariate analysis
Age 0.006 0.010 1.01 (0.99,1.03) 0.563
BMI 0.027 0.026 1.03 (0.98,1.08) 0.311
FEV1, predicted % −0.003 0.004 1.00 (0.99,1.01) 0.555
Wheezing* 0.509 0.228 1.66 (1.06,2.60) 0.026
Theophylline 0.134 0.515 1.14 (0.42,3.14) 0.794
Oral steroids −0.281 0.218 0.76 (0.49,1.16) 0.197
Inhaled LABA −0.363 0.486 0.70 (0.27,1.80) 0.455
Inhaled LAMA −0.369 0.245 0.69 (0.43,1.12) 0.133
Inhaled ICS* 0.412 0.210 1.51 (1.00,2.28) 0.049
Ischemic heart disease 0.312 0.362 1.37 (0.67,2.77) 0.389
Heart failure −0.549 0.537 0.58 (0.20,1.66) 0.307
Hypertension 0.409 0.220 1.50 (0.98,2.32) 0.063
Arrhythmia 0.438 0.487 1.55 (0.60,4.03) 0.368
Depression 1.294 0.797 3.65 (0.76,17.4) 0.105
Anxiety −0.124 0.823 0.88 (0.18,4.43) 0.880
CAT score* 0.085 0.017 1.09 (1.05,1.13) <0.001
mMRC score* 0.264 0.125 1.30 (1.02,1.66) 0.035
Abbreviations: BMI body mass index, FEV1 forced expiratory volume in the first second, ICS inhaled corticosteroids, LABA long-acting beta agonist, LAMA long-acting
muscarinic antagonist, CAT COPD assessment test, mMRC modified Medical Research Council, CI confidence interval
*p < 0.05
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night or in the early morning, and coughing or snoring
loudly. Symptoms including wheezing, phlegm, and the
use of inhaled corticosteroid may also have contributed
to poor sleep quality in these COPD patients.
Abbreviations
BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic
obstructive lung disease; FEV1, forced expiratory volume in the first second;
FVC, forced vital capacity; GOLD, Global Initiatives for Chronic Obstructive
Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting beta agonists;
LAMA, long-acting muscarinic antagonist; mMRC, Modified Medical Research
Council; PSQI, Pittsburgh Sleep Quality Index; REM, rapid eye movement
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